Clinical Trial

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

Name: Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies — clinical trial record (NCT07444632)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-27

Trial Details

NCT Number	NCT07444632
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Lymphoid, Hodgkin Lymphoma
Enrollment	60 participants
Start Date	2026-05-28
Primary Completion	2030-09-30 (estimated)
Study Completion	2032-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-26